Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials
- PMID: 16442208
- DOI: 10.1016/j.eururo.2005.12.031
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials
Abstract
Objectives: To provide tables that allow urologists to easily calculate a superficial bladder cancer patient's short- and long-term risks of recurrence and progression after transurethral resection.
Methods: A combined analysis was carried out of individual patient data from 2596 superficial bladder cancer patients included in seven European Organization for Research and Treatment of Cancer trials.
Results: A simple scoring system was derived based on six clinical and pathological factors: number of tumors, tumor size, prior recurrence rate, T category, carcinoma in situ, and grade. The probabilities of recurrence and progression at one year ranged from 15% to 61% and from less than 1% to 17%, respectively. At five years, the probabilities of recurrence and progression ranged from 31% to 78% and from less than 1% to 45%.
Conclusions: With these probabilities, the urologist can discuss the different options with the patient to determine the most appropriate treatment and frequency of follow-up.
Comment in
-
Re: Richard J. Sylvester, Adrian P.M. van der Meijden, Willem Oosterlinck, J. Alfred Witjes, Christian Bouffioux, Louis Denis and Donald W.W. Newling. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-77.Eur Urol. 2006 Sep;50(3):623-4; author reply 624-5. doi: 10.1016/j.eururo.2006.04.005. Epub 2006 May 4. Eur Urol. 2006. PMID: 16707208 No abstract available.
-
Identifying risk factors in patients with non-muscle-invasive bladder cancer: clinical implications.Eur Urol. 2011 Oct;60(4):721-3. doi: 10.1016/j.eururo.2011.07.065. Epub 2011 Aug 5. Eur Urol. 2011. PMID: 21840119 No abstract available.
Similar articles
-
Predicting recurrence and progression in non-muscle-invasive bladder cancer using European organization of research and treatment of cancer risk tables.Urol J. 2009 Summer;6(3):189-93. Urol J. 2009. PMID: 19711273
-
Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.Chin Med J (Engl). 2006 Nov 5;119(21):1821-8. Chin Med J (Engl). 2006. PMID: 17097038
-
Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.Int J Urol. 2009 Mar;16(3):279-86. doi: 10.1111/j.1442-2042.2008.02235.x. Epub 2009 Jan 20. Int J Urol. 2009. PMID: 19207609
-
[EORTC risk tables--a new diagnostic tool in urology].Pol Merkur Lekarski. 2009 Dec;27(162):524-8. Pol Merkur Lekarski. 2009. PMID: 20120722 Review. Polish.
-
The treated natural history of high risk superficial bladder cancer: 15-year outcome.J Urol. 1997 Jul;158(1):62-7. doi: 10.1097/00005392-199707000-00017. J Urol. 1997. PMID: 9186324 Review.
Cited by
-
Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer.Bladder Cancer. 2024 Oct 23;10(3):167-182. doi: 10.3233/BLC-240032. eCollection 2024. Bladder Cancer. 2024. PMID: 39493816 Free PMC article. Review.
-
A higher De Ritis ratio (AST/ALT) is a risk factor for progression in high-risk non-muscle invasive bladder cancer.Oncotarget. 2021 Apr 27;12(9):917-922. doi: 10.18632/oncotarget.27944. eCollection 2021 Apr 27. Oncotarget. 2021. PMID: 33953845 Free PMC article.
-
The Impact of Non-Compliance to a Standardized Risk-Adjusted Protocol on Recurrence, Progression, and Mortality in Non-Muscle Invasive Bladder Cancer.Cancer Manag Res. 2021 Mar 31;13:2937-2945. doi: 10.2147/CMAR.S299148. eCollection 2021. Cancer Manag Res. 2021. PMID: 33833577 Free PMC article.
-
MicroRNA‑34a‑5p serves as a tumor suppressor by regulating the cell motility of bladder cancer cells through matrix metalloproteinase‑2 silencing.Oncol Rep. 2021 Mar;45(3):911-920. doi: 10.3892/or.2020.7910. Epub 2020 Dec 24. Oncol Rep. 2021. PMID: 33650650 Free PMC article.
-
Is it oncologically safe performing simultaneous transurethral resection of the bladder and prostate? A meta-analysis on 1,234 patients.Int Urol Nephrol. 2012 Oct;44(5):1325-33. doi: 10.1007/s11255-012-0183-3. Epub 2012 Jun 19. Int Urol Nephrol. 2012. PMID: 22710969
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical